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Abstract
Background: HER2/neu is an oncogene that facilitates neoplastic transformation due to its ability to transduce
growth signals in a ligand-independent manner, is over-expressed in 20-30% of human breast cancers correlating
with aggressive disease and has been successfully targeted with trastuzumab (Herceptin
®). Because trastuzumab
alone achieves only a 15-30% response rate, it is now commonly combined with conventional chemotherapeutic
drugs. While the combination of trastuzumab plus chemotherapy has greatly improved response rates and
increased survival, these conventional chemotherapy drugs are frequently associated with gastrointestinal and
cardiac toxicity, bone marrow and immune suppression. These drawbacks necessitate the development of new,
less toxic drugs that can be combined with trastuzumab. Recently, we reported that orally administered alpha-
tocopheryloxyacetic acid (a-TEA), a novel ether derivative of alpha-tocopherol, dramatically suppressed primary
tumor growth and reduced the incidence of lung metastases both in a transplanted and a spontaneous mouse
model of breast cancer without discernable toxicity.
Methods: In this study we examined the effect of a-TEA plus HER2/neu-specific antibody treatment on HER2/neu-
expressing breast cancer cells in vitro and in a HER2/neu positive human xenograft tumor model in vivo.
Results: We show in vitro that a-TEA plus anti-HER2/neu antibody has an increased cytotoxic effect against murine
mammary tumor cells and human breast cancer cells and that the anti-tumor effect of a-TEA is independent of
HER2/neu status. More importantly, in a human breast cancer xenograft model, the combination of a-TEA plus
trastuzumab resulted in faster tumor regression and more tumor-free animals than trastuzumab alone.
Conclusion: Due to the cancer cell selectivity of a-TEA, and because a-TEA kills both HER2/neu positive and HER2/
neu negative breast cancer cells, it has the potential to be effective and less toxic than existing chemotherapeutic
drugs when used in combination with HER2/neu antibody.
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Alpha-tocopheryloxyacetic acid (a-TEA) is an ether deri-
vative of naturally occurring vitamin E (alpha-toco-
pherol). Unlike vitamin E, which lacks in vivo anti-tumor
activity and fails to prevent cancer in humans [1,2], a-
TEA is directly cytotoxic to tumor cells [3-7] via a
mechanism that includes mitochondrial depolarization
and generation of reactive oxygen species leading to
apoptotic cell death [8-10] as has been reported for
alpha-tocopheryl succinate (a-TOS) [11]. Unlike alpha-
tocopheryl succinate (a-TOS), which is susceptible to
conversion to the apoptosis-inert tocopherol and succinic
acid by intestinal esterases, a-TEA is stable and induces
apoptosis of a variety of mouse and human cancer cell
lines while sparing normal cells [3,4,6,7]. More impor-
tantly, we reported recently that oral a-TEA significantly
inhibited the growth of transplanted murine breast can-
cer (4T1) and dramatically reduced the incidence of lung
metastases [7] and was able to suppress growth in a clini-
cally relevant spontaneous model of breast cancer
(MMTV-PyMT) without overt toxicity [6].
HER2/neu is a proto-oncogene that encodes a 185-kDA
tyrosine kinase receptor and is related to members of the
epidermal growth factor receptor family [12]. HER2/neu
promotes neoplastic transformation by virtue of its ability
to transduce growth signals in a ligand-independent man-
ner [13,14]. The HER2/neu protein is over-expressed in
20-30% of invasive human breast cancers [15,16], is asso-
ciated with aggressive disease [15,17] and has been suc-
cessfully targeted in HER2/neu
+, hormone receptor
positive or negative, breast cancer patients with trastuzu-
mab (Herceptin
®) [18-20], which is a humanized mono-
clonal antibody directed against the extracellular domain
of the HER2/neu protein. When used as a single agent,
trastuzumab is beneficial only in 15-30% of HER2/neu
+
breast cancer patients that express very high levels of
HER2/neu protein but efficacy can be enhanced when
combined with chemotherapeutic drugs [18,21]. Although
trastuzumab is widely used for the treatment of HER2/neu
over-expressing breast cancers, its mechanism of action is
still only partially understood. There is evidence that tras-
tuzumab inhibits proliferation and survival of breast can-
cer cells by mechanisms that include stimulation of
antibody-dependent cell-mediated cytotoxicity (ADCC)
[22,23], inhibition of angiogenesis [24,25], and enhance-
ment of endocytic degradation of HER2/neu, although the
latter finding remains controversial [23].
Given the different mechanisms by which a-TEA and
trastuzumab mediate tumor cell death [3,26-29], we
hypothesized that combining a-TEA with HER2/neu-
specific antibody will result in enhanced anti-tumor
activity against HER2/neu-expressing breast cancer.
In this report we evaluated the anti-tumor activity of
concurrent a-TEA and anti-HER2/neu antibody
treatment against HER2/neu-expressing murine mam-
mary and human breast cancer cells in vitro and on
established HER2/neu
+ human breast cancer in a murine
xenograft tumor model. We report that a-TEA induces
cell death of several mouse mammary and human breast
cancer cell lines irrespective of HER2/neu status. More
importantly, when combined with anti-HER2/neu anti-
body, a-TEA improves the efficacy of trastuzumab ther-
apy resulting in complete regression of established
HER2/neu
+ human breast cancer xenografts. These
results suggest that a-TEA is a viable less toxic agent
which can be used in combination with trastuzumab for
the treatment of HER2/neu
+ breast cancer.
Methods
Reagents
a-Tocopheryloxyacetic acid
Alpha-TEA [(2,5,7,8-tetramethyl-(2R-(4R,8R,12-trimethyl-
tridecyl) chroman-6-yloxy) acetic acid)] was synthesized at
The Arizona Cancer Center Synthetic Shared Resource at
The University of Arizona (Tucson, AZ) using modified
previously described methods [3,30,31]. Purity and identity
was confirmed by high-performance liquid chromatogra-
phy and nuclear magnetic resonance analysis. To make a-
TEA soluble in aqueous culture media for in vitro assays,
a-TEA was vesiculated (Va-TEA) by sonication of an a-
TEA thin film in the presence of PBS as previously
described [7].
Antibodies
The anti-rat neu antibody (7.16.4) was generated as
described previously [32]. The non-specific mouse IgG2a
antibody was purchased from Chemicon (cat#: PP102,
Chemicon Int. Temecula, CA). Trastuzumab (Herceptin
®)
and rituximab (Rituxan
®) were purchased from Genentech
(San Francisco, CA).
Tumor cells and cell culture
Rat HER2/neu positive (MMC) and HER2/neu negative
(ANV) mouse mammary tumor cell lines [33] and human
HER2/neu positive (MDA-MB-453) and HER2/neu nega-
tive (MDA-MB-231) breast cancer cell lines were used for
these studies. The human cell lines were purchased from
American Type Culture Collection (ATCC, Manassas,
VA). The MMC and ANV tumor cell lines were main-
tained in RPMI-1640 with glucose and L-glutamine
(Lonza, Walkersville, MD) containing 100 U/mL penicillin,
100 mg/mL streptomycin (Hyclone Laboratories, Logan,
UT), 0.025 mg/mL Amphotericin B (Hyclone), 0.1 mM
non-essential amino acids (Lonza), 1 mM sodium pyruvate
(Lonza), 2 mM L-glutamine (Lonza) and 10% fetal bovine
serum (FBS) (Invitrogen, Carlsbad, CA). The MDA-MB-
231 and MDA-MB-453 tumor cell lines were maintained
in RPMI-1640 containing 50 μg/mL Gentamicin (Lonza),
0.1 mM non-essential amino acids (Lonza), 1 mM sodium
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FBS (Invitrogen, Carlsbad, CA). All cells were maintained
in log phase in a humidified chamber at 37°C with 7%
CO2.
In vitro studies
To determine the cytotoxic effect of a-TEA, tumor cells
were plated in three to six replicates in 96-well plates and
allowed to adhere overnight. The cells were then treated
with media alone or increasing doses of Va-TEA for
24 hours (MMC, ANV), 48 hours (MDA-MB-231) or
72 hours (MDA-MB-453). Cell survival was determined
using the Thiazyl Blue Tetrazolium Bromide (MTT)
assay [34]. Briefly, MTT (Sigma, St. Louis MO) in serum-
free media was added to achieve a concentration of
5 mg/mL. After a 2 h incubation (37°C, 7% CO2), the
plate was centrifuged (500 xg, 5 min), the supernatant
removed and the dark-blue metabolite was dissolved in
DMSO. Cell killing was then determined by measuring
absorption at 560 nm.
In order to determine the combined effect of a-TEA
plus anti-HER2/neu antibody on cell survival, tumor cells
were plated in 6 replicates in 96-well plates and allowed to
adhere overnight. The cells were then simultaneously trea-
ted with pre-determined sub-optimal doses of a-TEA
(20 μM for MMC and ANV, and 10 μM for MDA-MB-
453 and MDA-MB-231) and HER2/neu-specific antibody
(20 μg/mL of the 7.16.4 anti-rat HER2/neu antibody for
MMC and ANV; 10 μg/mL trastuzumab for MDA-MB-
453; 20 μg/mL trastuzumab for MDA-MB-231). The
respective isotype antibodies were mouse IgG2a antibody
(MMC, ANV) and rituximab (MDA-MB-453, MDA-MB-
231). After 5 days, surviving cells were assessed by MTT
assay. To detect apoptosis, MDA-MB-453 cells were
plated in 6-well plates overnight and then treated with
10 μMV a-TEA and 10 μg/mL trastuzumab (or isotype
antibody) for 72 hours. Cells were collected using 10 mM
EDTA and stained using the PE-Annexin-V/7AAD apop-
tosis detection kit (BD Pharmingen, San Diego, CA)
according to the manufacturer’s instructions and analyzed
by flow-cytometry using a LSR-II flow cytometer (BD
Bioscience) with data acquisition using DIVA software
(BD Bioscience). Cells positively staining with PE-
Annexin-V were considered to be apoptotic.
Western Immunoblotting
MDA-MB-453 tumor cells were plated in 6-well culture
dishes overnight and then treated with 10 μMV a-TEA or
40 μg/mL trastuzumab (or isotype antibody) for 24 h. Cell
lysates were prepared using Complete Lysis-M Buffer
(Roche Applied Sciences) containing protease inhibitors
and phosphatase inhibitors (both Roche Applied Sciences).
The lysates were clarified (14,000 xg, 15 min, 4°C) and
protein content was determined by BCA (Thermo
Scientific, Rockford, IL). Equal amounts of protein (10 μg)
were separated on pre-cast TGX-Criterion Any-kd SDS
gels (BIO-RAD, Hercules, CA), transferred to Amersham
Hybond-ECL nitrocellulose membrane (GE Healthcare).
Membranes were blocked with Odyssey Blocking Buffer
(LI-COR Biosciences, Lincoln, NE). Primary antibodies
used were: anti-phosphorylated-(Ser473)-AKT (1:1000,
Cell Signaling Technology, Denvers, MA); anti-AKT
(1:1000, Cell Signaling); anti-GAPDH (1:3000, Millipore,
Temecula, CA). Primary antibodies were diluted in phos-
phate-buffered saline (PBS) containing 5% bovine serum
albumin (BSA) and 0.1% Tween-20 (PBS/T-5%-BSA).
After washing in PBS containing 0.1% Tween-20 (PBS/T),
the membranes were exposed to anti-rabbit-HRP-conju-
gated (Cell Signaling) or anti-mouse-HRP-conjugated
(eBioscience, San Diego, CA) secondary antibodies (both
1:10,000). Bands were visualized using SuperSignal West-
Pico chemiluminescence substrate (Thermo Scientific).
Films were scanned and band intensities were quantified
using ImageJ software [35].
Flow cytometry
To determine HER2/neu expression in MMC and ANV
cells, tumor cells were incubated with the anti-rat HER2/
neu antibody (7.16.4) and then stained with a FITC-conju-
gated goat-anti mouse IgG antibody (Caltag, Burlingame,
CA). MDA-MB-453 and MDA-MB-231 cells were stained
with a FITC-conjugated anti-human erbB2/HER2 anti-
body (clone 24D2, Biolegend, San Diego, CA). FITC-con-
jugated isotype antibodies were included as controls. Cells
were interrogated using a FACScan flow cytometer (BD
Biosciences, San Jose, CA) with data acquisition using
CellQuest (BD Biosciences) or a LSR-II flow cytometer
(BD Bioscience) with data acquisition using DIVA soft-
ware (BD Bioscience). Data were analyzed using FlowJo
v8.8.4 (Tree Star Inc., Ashland, OR). To determine HER2/
neu expression in vivo, tumors were resected and minced
using a scalpel in HBSS (Lonza) containing 5 mM EDTA.
The tumor cells were then pushed in succession through
metal, 70 μma n d4 0μm nylon sieves (BD Biosciences Dis-
covery Labware, Two Oaks, CA). The resulting tumor cell
suspension was assessed for cell viability using the LIVE/
DEAD Fixable Violet stain (Invitrogen, Carlsbad, CA) and
used for flow cytometric analysis of HER2/neu expression.
Animal studies
Six- to eight-week-old female severe combined immuno-
deficiency (SCID; strain CB17SC) mice were bred at the
University of Arizona Cancer Center Experimental
Mouse Shared Services (EMSS) or purchased from Taco-
nic Farms Inc. (Hudson, NY). Mice were housed in
micro-isolator cages at the animal facilities of either the
University of Arizona (Tucson, AZ) or the Earle A. Chiles
Research Institute (Providence Portland Medical Center,
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Animal Care (NIH publication No. 85-23). All studies
were reviewed and approved by the institutional animal
c a r ea n du s ec o m m i t t e e( I A C U C )o fT h eU n i v e r s i t yo f
Arizona or the Earle A. Chiles Research Institute.
For the human xenograft studies, 1 × 10
7 viable MDA-
MB-453 breast cancer cells were injected s.c. into the
right mammary fat pad of SCID mice. After tumor estab-
lishment (day 15 post-tumor cell injection), the mice
remained on standard (nutrient-matched) chow or were
transferred to chow containing 1 g/kg a-TEA (0.1% diet,
Harlan Teklad) resulting in an intake of ~2 mg of a-TEA
per day per mouse (equivalent to ~100 mg a-TEA per kg
b o d yw e i g h t ) .T h em i c ew e r em a i n t a i n e do nt h ea-TEA
diet until day 63 post-tumor implantation and were then
transferred to standard chow. Trastuzumab (40 μgp e r
injection) or isotype control (rituximab) were adminis-
tered by intraperitoneal (i.p.) injection on days 15, 17, 19,
22, 24, 26, 29, 31, 33, 36, 38, 40 post-tumor transplanta-
tion. Tumor growth was monitored by measuring the
tumor length (L) and width (W) using calipers and calcu-
lating the tumor volume as: V = (L × W × W/2).
Histology and determination of in vivo cell proliferation
and apoptosis
Tumors were resected on day 30 post-tumor injection and
tissues were fixed in 10% buffered formalin for 24 h, paraf-
fin-embedded, and 3 μm sections were stained with hema-
toxylin and eosin (H&E) and evaluated by a veterinary
pathologist. Cell proliferation was determined on de-paraf-
finized 3 μm sections using antibodies specific for the
nuclear antigen Ki-67 (Novocastra Laboratories, Newcastle
upon Tyne, UK, cat#: NCL-ki67p). Deparaffinization, anti-
gen retrieval and primary antibody staining, detection and
amplification of the primary antibody, and hematoxylin
counterstaining was performed on a Discovery XT Auto-
mated Immunostainer (Ventana Medical Systems, Tucson,
AZ) using Ventana Medical Systems validated reagents.
Ki-67 was detected using an anti-rabbit biotinylated sec-
ondary antibody and by using biotinylated-streptavidin-
HRP and a DAB (diaminobenzidine) system (DAPMap).
Apoptosis was determined on deparaffinized 5 μms e c -
tions by terminal deoxynucleotidyl transferase-mediated
dUTP nick end labeling (TUNEL). The TUNEL assay was
performed using the ApopTag Fluorescein In Situ Apop-
tosis Detection Kit (Millipore, Temecula, CA) according to
the manufacturer’s protocol. Sections were counterstained
with propidium iodide in Antifade (Millipore). Sections
were evaluated using a Nikon Eclipse TE2000-S inverted
microscope (Nikon Instruments Inc., Melville, NY) with
epifluorescence capabilities using the B-2E/C filter set
(excitation: 465-495 nm band pass; dichromatic mirror:
505 nm long pass; emission: 515-555 nm band pass) and
the Y-2E/C filter set (excitation: 540-580 nm band pass;
dichromatic mirror: 595 nm long pass; emission 600-660
nm band pass). Pictures were acquired using a DS-Fi1
color camera (Nikon Instruments Inc.) and the Nikon
Imaging System Basic Research (NIS-Br, version 3.2) soft-
ware (Nikon Instruments Inc.). Ki-67 or TUNEL positive
cells were counted in 5 microscopic fields (40× magnifica-
tion) per section from three mice per treatment group
using the NIS-Br software.
Statistical analysis
Statistical significance of differences among data sets of
treatment groups was assessed either by Student’s t-test,
where applicable, or by one-way analysis of variances
(ANOVA), including Tukey-Kramer post tests for multiple
comparisons. Analyses were performed using Prism soft-
ware (GraphPad, San Diego, CA). Probability values (P) of
< 0.05 were considered indicative of significant differences
between data sets. For the xenograft studies, mean tumor
size across the study time points for the trastuzumab and
trastuzumab+a-TEA groups was modeled using a non-
linear mixed model. The mean size was represented by a
4-parameter logistic regression model, with separate slope
and lower asymptote parameters for the different treat-
ment groups. Due to the intra-animal correlation across
time, a random lower asymptote was inserted into the
model to allow the remission curves of different animals
to vary. Model estimation was performed using PROC
NLMIXED in SAS v. 9.2 (SAS, Cary, NC). The percentage
of tumor-free animals at day 63 was compared between
groups using Fisher’s exact test. Hochberg’sm e t h o dw a s
used to adjust the significance level for multiple compari-
sons. The absence of tumor across the study time points
for the trastuzumab and trastuzumab+a-TEA groups was
modeled using generalized estimating equations. The
model with a logit link had different linear slopes and a
common quadratic slope across days. Model parameters
were assessed for significance using empirical standard
error estimates. The intra-subject covariance matrix was
autoregressive with order 1.
Results
a-TEA induces cell death of mouse mammary and human
breast cancer cells independent of HER2/neu expression
In initial studies, we evaluated the expression level of sur-
face HER2/neu in several mouse and human breast can-
cer cell lines as well as their susceptibility to a-TEA
treatment. HER2/neu expression was confirmed by flow
cytometry in the MMC, and MDA-MB-453 cell lines
(Figure 1A). In contrast, the ANV and MDA-MB-231 cell
lines expressed minimal HER2/neu (Figure 1A). To
ascertain the susceptibility of tumor cells to a-TEA, they
were exposed to increasing doses of a-TEA and cell sur-
vival was determined. The data (Figure 1B) show that
irrespective of HER2/neu status, both mouse mammary
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in a dose-dependent fashion with IC50 values ranging
from 15 μMt o5 1μM. The ability of a-TEA to kill breast
cancer cells irrespective of HER2/neu status suggests that
it could be effective for treating HER2/neu
+ as well as
HER2/neu
- breast cancer.
Enhanced tumor cell killing by a-TEA + anti-HER2/neu
antibody treatment
We next compared tumor cytotoxicity induced by a-
TEA + anti-HER2/neu antibody using both murine
HER2/neu
+ (MMC) and HER2/neu
- (ANV) and human
HER2/neu
+ (MDA-MB-453) and HER2/neu
- (MDA-MB-
231) breast cancer cell lines. To achieve this goal, tumor
cells were treated with sub-optimal doses of a-TEA
alone, anti-HER2/neu antibody alone or a-TEA + anti-
HER2/neu antibody. The data show that combining a
sub-optimal dose of a-TEA with HER2/neu-specific
antibody resulted in an enhanced cytotoxic effect on the
HER2/neu
+ breast cancer cell lines (Figure 2A and 2B).
This is in contrast to the HER2/neu
- cell lines where we
observed no significant reduction in tumor cell survival
in anti-HER2/neu antibody-treated cells and no
enhancement of tumor cell growth reduction beyond
the a-TEA-mediated effect (Figure 2C and 2D).
a-TEA plus trastuzumab combination treatment induces
apoptosis and reduces pro-survival signaling
Previously it has been shown by us [6,7] and others [3,4]
that a-TEA-mediated tumor cell cytotoxicity is partially
mediated through the induction of apoptosis. In order to
determine if a-TEA also induced apoptosis in the human
HER2/neu-expressing MDA-MB-453 tumor cell line, we
examined Annexin-V staining after a-TEA treatment. The
data in Figure 3A show that a-TEA treatment increased
the fraction of apoptotic cells approximately 3-fold com-
pared to untreated (isotype-treated) cells. Trastuzumab
alone did not induce apoptosis of MDA-MB-453 cells.
Furthermore, there was no increase in apoptotic cells
when cells were treated with a-TEA + trastuzumab com-
pared to a-TEA treatment. One of the mechanisms of
trastuzumab-mediated tumor cell reduction is the inhibi-
tion of pro-survival signaling through the phosphatidylino-
sitol 3-kinase (PI3K) pathway. HER2/neu over expression
leads to activation of PI3K that activates AKT by phos-
phorylation. AKT exerts its survival role via a diverse array
of substrates, which control key cellular processes, includ-
ing apoptosis, cell cycle progression, transcription, and
translation [36]. Therefore AKT phosphorylation status
(pAKT) was used as a surrogate marker to determine the
effect of trastuzumab on MDA-MB-453 tumor cells. The
data (Figure 3B) show that trastuzumab treatment resulted
in decreased pAKT levels, suggesting reduced signaling
through HER2/neu. Previously, it has been shown that a-
TEA reduced tumor cell viability not only by activation of
pro-apoptotic pathways but also by reducing PI3K-
mediated growth/survival signaling [8,37]. a-TEA treat-
ment also decreased pAKT levels compared to untreated
cells (Figure 3B). More importantly, the data show that the
combination of a-TEA+trastuzumab reduced pAKT level
Figure 1 Murine and human tumor cells are susceptible to a-TEA irrespective of HER2/neu status.( A )H E R 2 / neu expression was
determined by flow cytometry. The murine MMC and ANV tumor cells were stained with a rat-HER2/neu-specific antibody (7.16.4) and then with
a FITC-conjugated anti-mouse-IgG antibody. The human MDA-MB-453 and MDA-MB-231 tumor cells were stained using a FITC-conjugated
human-HER2/neu-specific antibody. Cells were gated on light scatter. (B) Tumoricidal effect of Va-TEA. Tumor cells were allowed to adhere
overnight and were then treated with media alone or increasing doses of Va-TEA. Cell survival was determined by MTT assay after 24 h (MMC,
ANV), 48 h (MDA-MB-231) or 72 h (MDA-MB-453). Results are expressed as mean percentage ± SD of untreated cells (media alone). Non-linear
regression analysis was performed to determine half-maximal inhibitory concentrations (IC50).
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pared to untreated cells (Figure 3B). Taken together, these
results suggest that, while the major mechanism of a-TEA
+trastuzumab-mediated tumor cell reduction in vitro is
the induction of apoptosis by a-TEA, inhibition of pro-
survival signaling through AKT may also contribute to the
superior cytotoxic effect of the combination treatment.
a-TEA plus trastuzumab combination therapy suppresses
human breast cancer and leads to complete tumor
regression
We next wanted to test the efficacy of concurrent a-TEA
and trastuzumab (Herceptin
®) treatment in suppressing
established HER2/neu
+ human mammary cancer. To
achieve this goal, SCID mice were injected with 1 × 10
7
HER2/neu-expressing MDA-MB-453 tumor cells.
Following tumor establishment on day 15, mice were
randomized and placed on a-TEA-supplemented mouse
chow and trastuzumab therapy was initiated. The mice
received 12 i.p. injections of trastuzumab (40 μg/injec-
tion) given 3 times a week until day 40 post-tumor injec-
tion. This dose of trastuzumab (2 mg/kg) has been
previously reported to inhibit tumor growth in xenograft
models [38] and is equivalent to the maintenance dose
(2 mg/kg) administered to breast cancer patients [39].
The data (Figure 4A) show that when compared to mice
Figure 2 Susceptibility of HER2/neu positive and negative tumor cell lines to a-TEA + anti-HER2/neu antibody. MMC (HER2/neu
+) or ANV
(Her2/neu
-) cells were allowed to adhere overnight. MMC and ANV cells were then treated with 20 μg/mL of anti-HER2/neu antibody (7.16.4), 20
μg/mL of mouse IgG2a antibody (isotype) or 20 μMo fV a-TEA. MDA-MB-453 (HER2/neu
+) and MDA-MB-231 cells were treated with 10 μg/mL
(MDA-MB-453) or 20 μg/mL (MDA-MB-231) trastuzumab or rituximab (isotype) or 10 μMV a-TEA. After a 5 day exposure, cell survival was
determined by MTT assay. Combined results from two to three independent experiments are expressed as mean percentage ± SD of untreated
cells (isotype) cells.
Hahn et al. BMC Cancer 2011, 11:471
http://www.biomedcentral.com/1471-2407/11/471
Page 6 of 12on the control diet (untreated or isotype-treated), a-TEA
(+/- isotype) or trastuzumab individually inhibited
growth of established MDA-MB-453 tumors. By day 40,
tumors had completely regressed in 5 of 10 mice (50%)
in the trastuzumab group compared to 0 of 10 in the
a-TEA group. The anti-tumor response was most robust
in the a-TEA + trastuzumab group where tumor regres-
sion occurred in 6 of 9 animals (67%) by day 40. At the
end of a-TEA treatment (day 63 post-tumor injection),
the tumor sizes of the remaining mice in the trastuzumab
Figure 3 Mechanism of a-TEA and trastuzumab-mediated tumor cell inhibition. (A) MDA-MB-453 tumor cells were treated with Va-TEA
and trastuzumab (or isotype antibody) for 72 hours. Cells were collected and analyzed for apoptosis by PE-Annexin-V stain. Mean frequency ±
SD of apoptotic cells (PE-Annexin-V positive) is shown from three independent experiments. (B) MDA-MB-453 tumor cells were treated with Va-
TEA and trastuzumab (or isotype antibody) for 24 hours. Phosphorylated-(Ser473)-AKT, total AKT and GAPDH levels were determined by western
immunoblotting. Numbers indicate fold-change over untreated (isotype-treated) cells.
Figure 4 Tumor regression by a-TEA plus trastuzumab treatment. SCID mice (n = 9 to 10 mice per group) received a s.c. injection of MDA-
MB-453 cells. After tumor establishment (day 15 post-tumor injection), mice received a-TEA in the diet (~2 mg/day/mouse) until day 63 (red bar)
or 40 μg trastuzumab by i.p. injection, every 2 to 3 days for a total of 12 injections until day 40 (green bar). One mouse in the a-TEA +
trastuzumab group died of unknown cause on day 35 post-tumor cell injection and was excluded from analysis. (A) Individual tumor volumes.
(B) Tumor frequency.
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ment levels (Figure 4B). This is in contrast to the combi-
nation treatment (a-TEA + trastuzumab) that continued
to cause tumor regression resulting in 9 of 9 tumor-free
mice (100%) by the end of a-TEA treatment (day 63).
Tumor recurred in one mouse in this group 7 days after
discontinuation of a-TEA diet (data not shown). The
percentage of tumor-free animals in the a-TEA + trastu-
zumab group was significantly higher than in the trastu-
zumab alone group (p = 0.033) and all other treatment
groups (p < 0.0001 for all comparisons). In addition, the
rate at which the percentage of animals with tumors
decreased from day 15 to 63 was significantly greater for
the a-TEA + trastuzumab group (p = 0.029) compared to
the trastuzumab alone group (Figure 4B). Accordingly,
the rate at which the tumor volume decreased from day
15 to 63 was also significantly greater for the a-TEA +
trastuzumab group (p = 0.030) compared to the trastuzu-
mab group.
Effect of a-TEA plus trastuzumab treatment on HER2/neu
expression in vivo
The efficacy of trastuzumab depends on the stability of
HER2/neu expression on breast cancer during intervening
trastuzumab or adjuvant chemotherapy treatment. To
address the concern that trastuzumab, or the a-TEA+tras-
tuzumab combination treatment may result in down regu-
lation of HER2/neu, we determined HER2/neu expression
on tumor cells recovered from mice after 15 days of a-
TEA+trastuzumab therapy (day 30 post-tumor injection).
Cell surface HER2/neu expression remained high on
tumor cells after trastuzumab, a-TEA or a-TEA+trastuzu-
mab treatment (Figure 5) compared to tumor cells from
isotype-treated mice and HER2/neu expression levels of
Figure 5 a-TEA inhibits tumor growth without modulating HER2/neu expression. SCID mice with established MDA-MB-453 tumors (day 15
post-tumor injection) received a-TEA in the diet (~2 mg/day/mouse) or 40 μg trastuzumab by i.p. injection, every 2 to 3 days for a total of 7
injections. On day 30 post-tumor injection, tumors were mechanically dissociated and a single cell suspension was prepared and analyzed for
HER2/neu expression by flow cytometry. HER2/neu expression of MDA-MB-453 tumor cells used for transplantation is shown for comparison (pre-
injection). Cells were gated on light scatter and non-viable cells were excluded from the analysis using viability stain.
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injection).
Effect of a-TEA plus trastuzumab on in vivo tumor
proliferation and apoptosis induction
In order to determine the mechanism of a-TEA+trastu-
zumab-mediated tumor suppression in vivo, we assessed
in situ apoptosis and proliferation in tumors of three ran-
domly selected mice per treatment group. Because a-
TEA+trastuzumab therapy resulted in a 100% cure rate
on day 63 post-tumor injection, tumors were obtained
from mice at an intermediate time point (day 30 post-
tumor injection) after 15 days of a-TEA+trastuzumab
treatment. Serial sections of each tumor in the isotype-
treated, a-TEA, trastuzumab and a-TEA+trastuzumab
treatment groups were histochemically stained with
hematoxylin & eosin (H&E), analyzed for apoptosis by
TUNEL assay (Figure 6A and 6B) or immunostained with
Ki-67-specific antibody (Figure 6C and 6D).
All tumors had a morphologic diagnosis of carcinoma,
and displayed a similar pattern with multiple lobules com-
posed of solid sheets of cells separated by variably dense
fibrovascular stroma. Bi- and occasionally multi-nucleate
cells and numerous atypical mitotic figures were present.
Tumors varied in the amount of average number of
mitoses per high powered field (mitotic index). Tumors in
the isotype-treated group had mitotic indices in excess of
10. Tumors in the trastuzumab group had mitotic indices
of 7 or more and tumors from the a-TEA-treated group
had mitotic indices between 5 and 10. In contrast, Tumors
from the a-TEA+trastuzumab group had the lowest mito-
tic indices of 4 and 5. Analysis of in situ apoptosis showed
that compared to isotype-treated mice, a-TEA, trastuzu-
mab and a-TEA+trastuzumab treatment resulted in signif-
icant increases of TUNEL positive cells per field (Figure
6B). Compared to isotype-treated mice, a-TEA alone
resulted in 2.7-fold increase of TUNEL positive cells per
field, while trastuzumab alone resulted in a more moder-
ate 2-fold increase of TUNEL positive cells (Figure 6B).
The combination treatment resulted in the highest
amount of apoptosis resulting in a 3.3-fold increase over
isotype-treated mice. Immunostains with Ki-67-specific
antibody (Figure 6D) revealed significant reductions of Ki-
67 positive cells in all treatment groups compared to the
isotype-treated group ranging from 1.7-fold (trastuzumab)
to 2.5-fold (a-TEA+trastuzumab) reduction. Taken
together, these data suggest that the mechanism of tumor
regression is a combination of induction of apoptosis and
reduced tumor cell proliferation.
Discussion
Despite recent advances in treatment, HER2/neu positive
or negative breast cancer continues to be a major cause
of death in women. a-TEA is an orally active semi-
synthetic analog of vitamin E, which has demonstrated
anti-tumor activity against several breast cancers in vitro
and in vivo. Trastuzumab (Herceptin
®), a humanized
antibody that targets the extracellular domain of HER2/
neu, has become standard of care for the treatment of
HER2/neu over-expressing early stage and metastatic
breast cancer. However, trastuzumab is effective in only a
small percentage of patients with high HER2/neu
+
tumors resulting in only a 15-30% response rate [18,21],
which can be significantly increased to 50-80% by the
addition of chemotherapeutic drugs [40]. In this study we
evaluated a novel combination therapy modality consist-
ing of oral a-TEA and HER2/neu-specific antibody. Our
data demonstrate the capability of a-TEA to efficiently
kill mouse mammary and human breast cancer cell lines
irrespective of the expression level of HER2/neu.T h i s
finding suggests that HER2/neu expression is not
required for a-TEA-mediated tumor cytotoxicity and
that HER2/neu-independent pathways may be operative
in a-TEA-mediated killing of HER2/neu-expressing
tumor cells. Furthermore, the ability of a-TEA to kill
breast cancer cells irrespective of HER2/neu status sug-
gests that it could be effective for treating HER2/neu
+ as
well as HER2/neu
- breast cancers. This finding led us to
hypothesize that combining a-TEA with trastuzumab
will result in an enhanced antitumor response. Our data
demonstrate a direct correlation between HER2/neu
expression and susceptibility to HER2/neu-specific anti-
body. The MMC and MDA-MB-453 cell lines exhibiting
high HER2/neu expression were susceptible to HER2/neu
antibody treatment. Combining sub-optimal doses of a-
TEA (20 μM for MMC, and 10 μM for MDA-MB-453)
with HER2/neu-specific antibody resulted in an enhanced
cytotoxic effect against the HER2/neu
+ cell lines that was
absent in the HER2/neu
- cell lines (ANV and MDA-MB-
231). This result suggests that lower doses of a-TEA may
be therapeutic if combined with HER2/neu-specific anti-
body. The modest efficacy of the combination treatment
in vitro is not surprising since the major in vitro mechan-
ism of trastuzumab is thought to be growth inhibition,
while the major in vivo mechanism of trastuzumab anti-
tumor activity, antibody-dependent cell-mediated cyto-
toxicity [22,41] and cross-priming by antigen-presenting
cells (APC), are lacking in the in vitro system. This is cor-
roborated by our results that trastuzumab in vitro did not
induce apoptosis in MDA-MB-453 tumor cells but
reduced the levels of activated AKT which is an impor-
tant survival and growth signal, suggesting that the main
trastuzumab effect in vitro is anti-proliferative. In con-
trast, a-TEA treatment in vitro resulted in significant
induction of apoptosis but also cooperated with trastuzu-
mab to further decrease activated AKT levels, providing a
mechanism of the enhanced tumor cell reduction in the
a-TEA+trastuzumab combination treatment. Our finding
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tumor tissue after a-TEA and/or trastuzumab treatment
is also consistent with the notion that the major mechan-
ism of anti-tumor efficacy of the combination treatment
in vivo is the result of the accumulation of apoptotic cell
death and restricted proliferation.
Using a xenograft model of human breast cancer, we
demonstrated for the first time that the combination of
a-TEA plus trastuzumab led to complete tumor regres-
sion in all treated animals compared to 50% regression in
mice that received trastuzumab alone. The enhancement
of the in vivo anti-tumor response in the combination
Figure 6 Immunohistologic analysis of tumor tissue after a-TEA plus trastuzumab treatment. SCID mice with established MDA-MB-453
tumors (day 15 post-tumor injection), mice received a-TEA in the diet (~2 mg/day/mouse) or 40 μg trastuzumab by i.p. injection, every 2 to 3
days for a total of 7 injections. On day 30 post-tumor injection tumors were resected. (A) Tumors were examined for apoptosis by TUNEL assay.
Representative images of tumor sections (20 × magnification) showing FITC-TUNEL-positive (green) and propipdium iodide counterstained (red)
cells. (B) Mean number of positive stained cells per field (40 × magnification) in sections from 3 mice per group. (C) Tumors were examined for
proliferation by Ki-67 immunostain. Representative images of tumor sections (20 × magnification) showing Ki-67-positive (brown) and
hematoxylin counterstained (blue) cells. (D) Mean number of positive stained cells per field (40 × magnification) in sections from 3 mice per
group.
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+
mouse mammary and human breast cancer cell lines.
An important aspect of the combination therapy is that
anti-tumor activity was detected using a trastuzumab
dose that is within the dose range administered to HER2/
neu
+ breast cancer patients [39], highlighting the transla-
tional potential of this novel combination therapy. Eva-
luation of HER2/neu expression at an intermediate time
point during the treatment regimen revealed no modula-
tion of HER2/neu expression. This finding suggests that
ongoing a-TEA or a-TEA+trastuzumab treatment of
established tumors does not impair HER2/neu expres-
sion, allowing for continued concurrent treatment of
such tumors with HER2/neu-specific antibody.
The anti-tumor effect in the a-TEA, trastuzumab and
the combination groups correlated with increased levels
of in situ apoptosis and decreased proliferation in the
tumors compared to the c group. The combination of a-
TEA+trastuzumab resulted in the highest level of in situ
apoptosis and the lowest level of proliferating cells that
correlated with the faster rate of tumor regression in the
combination group compared to the trastuzumab alone
group. These data suggest that induction of apoptosis
and reduction of tumor cell proliferation is a major
mechanism of breast cancer suppression by a-TEA+tras-
tuzumab therapy in vivo.
Conclusions
In summary, these findings demonstrate for the first time,
the efficacy of a stable orally active vitamin E derivative
(a-TEA) plus HER2/neu- s p e c i f i ca n t i b o d yi nt r e a t i n g
established HER2/neu positive breast cancer and highlight
the potential usefulness of a-TEA, a relatively non-toxic
chemotherapeutic agent, for treating HER2/neu positive or
negative breast cancer.
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